Section Arrow
NUVB.NYSE
- Nuvation Bio
Quotes are at least 15-min delayed:2024/12/24 12:47 EST
Last
 2.775
+0.105 (+3.93%)
Day High 
2.78 
Prev. Close
2.67 
1-M High
3.05 
Volume 
823.41K 
Bid
2.77
Ask
2.78
Day Low
2.605 
Open
2.68 
1-M Low
2.51 
Market Cap 
898.63M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 2.68 
20-SMA 2.77 
50-SMA 2.62 
52-W High 4.1598 
52-W Low 1.43 
Exchange NYSE 
Valuation Estimation
EPS (Current/Estimated)
-2.18/-0.61
Enterprise Value
900.67M
Balance Sheet
Book Value Per Share
1.49
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.385-0.0181-4.49%-- 
CMNDClearmind Medicine1.68+0.46+37.70%0.16PE
CEROCERo Therapeutics Holdings0.0603+0.0098+19.41%-- 
RXRXRecursion Pharmaceuticals7.315+0.325+4.65%-- 
CDTConduit Pharmaceuticals0.0576+0.0031+5.69%-- 
Quotes are at least 15-min delayed:2024/12/24 12:47 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.